Glass half full view on Qtrly update
* vaccine industry size is a gigantic mkt
* thrive continues to thrive (no pun intended :》)
* better gross margins due to more profitable product mix adopted
* expected savings in the millions moving forward
* RFK Jnr (brain worm) aint stopping pple taking vaccines in US
* more than 50% new brands and big sales team
* ebitda positive still expected
* instos been buying a lot of shares of late
* Rick in the Q&A part of webinar said along these lines that they have something progressing well with other groups that you'd expect them to partner with in the ANZ but had to be careful in his answer as it wasn't finalized yet
* Strategic valuation still ongoing as well
* 12.5mil cash flow, and better debt facility terms, less likely need for CR
Add to My Watchlist
What is My Watchlist?
